CGIM
RPRX icon

Cannon Global Investment Management’s Royalty Pharma RPRX Stock Holding History

Cannon Global Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,000
Closed -$901K – 91
2025
Q2 		$901K Sell
25,000
-3,500
-12% -$116K 1.84% 14
2025
Q1 		$887K Sell
28,500
-2,000
-7% -$63.4K 1.56% 16
2024
Q4 		$778K Sell
30,500
-4,000
-12% -$106K 1.69% 16
2024
Q3 		$976K Buy
+34,500
New +$956K 1.56% 16

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cannon Global Investment Management's RPRX Position: Q3 2025 in Review

Cannon Global Investment Management sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 25,000 shares — an estimated $901K sold.

Cannon Global Investment Management first reported a position in RPRX in Q3 2024 and held it in 4 quarters. The position peaked at $976K in Q3 2024. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • Cannon Global Investment Management reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • Cannon Global Investment Management sold 25,000 Royalty Pharma shares in Q3 2025, an estimated $901K.
  • Cannon Global Investment Management first reported a position in Royalty Pharma in Q3 2024 and held it in 4 quarters.
  • Cannon Global Investment Management's Royalty Pharma position peaked at $976K in Q3 2024.
  • 487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Cannon Global Investment Management's 13F filing for Q3 2025, filed 28 Oct 2025.